Drug information of Fluvoxamine

Fluvoxamine


Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) antidepressant. Fluvoxamine affects chemicals in the brain that may become unbalanced and cause obsessive-compulsive symptoms. Fluvoxamine is used to treat social anxiety disorder (social phobia), or obsessive-compulsive disorders involving recurring thoughts or actions.

Mechanism of effect

The mechanism of action of Fluvoxamine maleate in obsessive compulsive disorder is presumed to be linked to its specific serotonin reuptake inhibition in brain neurons.

Pharmacodynamic

Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders.

Pharmacokinetics

The absolute bioavailability of Fluvoxamine maleate is 53%. Oral bioavailability is not significantly affected by food. Fluvoxamine maleate is extensively metabolized by the liver. The mean plasma half-life of Fluvoxamine at steady state after multiple oral doses of 100 mg/day in healthy, young volunteers was 15.6 hours. an average of 94% of drug-related products was recovered in the urine within 71 hours.

Dosage

Usual Adult Dose for Depression Investigational: Initial dose: 50 mg orally once a day at bedtime Maintenance Dose: 100 to 300 mg per day. The dose may be increased in 50 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved. Total daily doses of more than 100 mg should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime

Alerts

1-Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior 2-The pupillary dilation that occurs following use of many antidepressant drugs including Fluvoxamine maleate tablets may trigger an angle closure attack in a patient with anatomically narrow angles who do not have a patent iridectomy. 3-SSRIs and SNRIs, including Fluvoxamine maleate tablets, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. 4- Fluvoxamine maleate tablets should be used cautiously in patients with a history of mania. 5-Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including Fluvoxamine maleate tablets. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone (SIADH).

Points of recommendation

1-Since any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery 2-patients should be advised to avoid alcohol while taking Fluvoxamine maleate tablets. 3-Patients should be advised to notify their physicians if they develop a rash, hives, or a related allergic phenomenon during therapy with Fluvoxamine maleate tablets. 4-Treatment with Fluvoxamine should be discontinued if seizures occur or if seizure frequency increases.

Pregnancy level

C


Tags

Ask a Pharmacist


User's questions
    No comments yet.